vendredi 23 septembre 2016

Is glucose lowering efficient for CV events prevention in D2 patients?

Table 1. Major CVOTs With Glucose Lowering Medications in Patients With T2DM at High Risk of a CV Event
Trial NameAgent/
comparator
NPrimary
Endpoint
Follow-UpEnd of Trial HbA1c
(%)
Primary Outcome
HR
(95% CI)
ORIGINInsulin glargine/
conventional
12,5373-point MACE6.2 yearsInsulin 6.2
Control 6.5
Neutral
HR 1.02
(0.94 to 1.11)
SAVOR- TIMI 53Saxa

ts?gliptin/
placebo
16,4923-point MACE24 monthsSaxagliptin 7.7
Placebo 7.9
Neutral
HR 1.00
(0.89 to 1.12)
EXAMINEAlogliptin/ placebo53803-point MACE18 monthsAlogliptin 7.7
Placebo 8.0
Neutral
HR 0.96
(-1.16)
TECOSSitagliptin/
placebo
14,6714-point MACE36 monthsSitagliptin 7.1
Placebo 7.4
Neutral
HR 0.98
(0.99 to 1.08)
ELIXALixisenatide/
placebo
60684-point MACE25 monthsLixisenatide 7.4
Placebo 7.6
Neutral
HR 1.02
(0.89 to 1.17)
EMPA-REG OUTCOMEEmpagliflozin/
placebo
70203-point MACE37 monthsEmpagliflozin 7.8
Placebo 8.2
Superior to placebo
HR 0.86
(0.74 to 0.99)
LEADERLiraglutide/
placebo
93403-point MACE46 monthsLiraglutide 7.7
Placebo 8.1
Superior to placebo
HR 0.87
(0.78 to 0.97)
3-point MACE = composite of CV death and nonfatal MI or stroke; 4-point MACE = composite of CV death, nonfatal MI or stroke and hospitalization for unstable angina; CI = confidence interval; CVOT = cardiovascular outcomes trial; CV = cardiovascular; HbA1c = glycated hemoglobin; HR = hazard ratio; MI = myocardial infarction; T2DM = type 2 diabetes mellitus

Sources: Ryden L et al[3]; Sattar N, et al[4]; and Marso SP, et al.[15]

http://www.medscape.org/sites/conference/easd-2016?src=mkmcmr_conf_easd16_mscpedu_slides 

Aucun commentaire:

 
Paperblog